Sign In
Buy XBIT
$2.23
-0.0100 (-0.446%)
At Close: Jul 31, 2026
Why Are XBiotech Shares Trading Higher Today
02:56pm, Thursday, 28'th Apr 2022
The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French Nationa
XBiotech signe un accord de fabrication clinique
11:27am, Tuesday, 08'th Feb 2022 GlobeNewswire Inc.
XBiotech fabrique des médicaments à base d'anticorps pour Janssen Research & Development, LLC (Janssen), l'une des sociétés pharmaceutiques Janssen de Johnson & Johnson XBiotech fabrique des médi
XBiotech schließt Vertrag über klinische Herstellung ab
11:27am, Tuesday, 08'th Feb 2022 GlobeNewswire Inc.
XBiotech produziert Antikörper-Medikamente für Janssen Research & Development, LLC (Janssen), eines der Janssen Pharmaunternehmen von Johnson & Johnson XBiotech produziert Antikörper-Medikamente f�
XBiotech gibt bekannt, dass der erste Patient in die klinische Phase-I-Studie zu Natrunix-SQ, einer neuartigen Arthritis-Therapie, aufgenommen wurde
02:06pm, Thursday, 27'th Jan 2022 GlobeNewswire Inc.
Natrunix-SQ, eine von XBiotech entwickelte und hergestellte True Human-Antikörpertherapie, soll einen Durchbruch bei der Behandlung von arthritischen Erkrankungen erzielen Natrunix-SQ, eine von XBiot
XBiotech annonce le recrutement du premier patient dans l'essai clinique de phase I pour le nouveau traitement de l'arthrite Natrunix-SQ
02:06pm, Thursday, 27'th Jan 2022 GlobeNewswire Inc.
Natrunix-SQ, une thérapie à base d'anticorps True Human découverte et fabriquée chez XBiotech, vise à révolutionner le traitement des maladie arthritiques Natrunix-SQ, une thérapie à base d'an
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
02:50pm, Wednesday, 26'th Jan 2022 GlobeNewswire Inc.
Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease Natrunix-SQ, A True Human Antibody Therapy Discovered and
FDA genehmigt IND-Antrag von XBiotech im Bereich Rheumatologie
05:46pm, Monday, 13'th Dec 2021 GlobeNewswire Inc.
Start von Natrunix™, einer neuartigen True Human-Antikörpertherapie zur Behandlung rheumatischer Erkrankungen Start von Natrunix™, einer neuartigen True Human-Antikörpertherapie zur Behandlung r
La FDA approuve le demande de nouveau médicament expérimental de XBiotech en rhumatologie
05:46pm, Monday, 13'th Dec 2021 GlobeNewswire Inc.
Lancement d'un nouveau traitement à base d'anticorps True Human Natrunix™ pour traiter les maladies rhumatologiques Lancement d'un nouveau traitement à base d'anticorps True Human Natrunix™ pour
Wells Fargo & Company MN Sells 17,033 Shares of XBiotech Inc. (NASDAQ:XBIT)
09:38am, Sunday, 12'th Dec 2021 Transcript Daily
Wells Fargo & Company MN reduced its stake in XBiotech Inc. (NASDAQ:XBIT) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,484 shares of the biopharmaceutical companys stock after selling 17,033 shares during the period. Wells Fargo & Company []
XBiotech Announces Payment of Dividend to Holders of Common Stock
11:03am, Friday, 30'th Jul 2021
Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
XBiotech Stock Increased 7.41%: Why It Happened
05:23pm, Wednesday, 07'th Jul 2021
The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.
XBiotech Announces Dividend to Holders of Common Stock
04:30pm, Tuesday, 06'th Jul 2021
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up
XBiotech Announces Receipt of $75 Million from Sale of Antibody
11:46am, Wednesday, 30'th Jun 2021
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
08:30am, Wednesday, 23'rd Jun 2021
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Infla
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
07:08am, Monday, 19'th Apr 2021
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. T
